Close Menu

Takeda

The international firm is one of several pharmaceutical companies emphasizing new single-cell technologies to improve existing drugs and find new ones.

GenAhead said it will use the IP it had licensed from ERS for genome editing applications in pharmaceutical drug discovery and development.

The company announced agreements to use the Oncomine Dx Target Test in drug development programs with Daiichi Sankyo, Takeda, and Spectrum Pharmaceuticals.

Takeda will use Definiens' new cloud-based digital pathology platform to conduct analyses for its clinical biomarkers development programs.

HudsonAlpha researchers are expected to sequence 20,000 patient tumor and non-tumor samples for ORIEN's Avatar initiative by 2019.

The partners will develop a biomarker discovery platform based on Exosome Diagnostics' exosomal RNA sequencing technology.

The Avatar Research Program will collect de-identified genomic and clinical information from consenting patients treated at ORIEN cancer centers.

The partners will screen for molecules that could revive metabolic activity in heart tissue damaged by cardiovascular disease or failure.

NEW YORK (GenomeWeb) – Using a new in-phase assay, researchers led by Duke University's Allen Roses believe they have captured key differences in APOE and TOMM40 haplotypes between African-American, Caucasian, and West African populations.

Seattle Genetics will receive a $6 million milestone payment from Takeda Pharmaceutical after the first commercial sales of Adcetris in Australia, South Korea, and Mexico.

Pages

Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.

University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.

NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.

In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.